Peptide News Digest

#Memorial-Day

2 stories

Industry · View digest

Memorial Day Monday US News Vacuum — EASL Tuesday May 26 ASCO Embargo, EASL Wednesday May 27 Opens

Monday May 25 is the US Memorial Day federal holiday; SEC filings, FDA actions, US company press releases pause for the day. The week's news cycle picks up Tuesday with ASCO's embargoed virtual press briefing for credentialed media (a preview of Late-Breaking Abstracts ahead of the May 29 Annual Meeting opening in Chicago) and Wednesday with EASL 2026's opening in Barcelona. The combined Tuesday-Wednesday cycle delivers the most concentrated peptide-mechanism data of any week in 2026 — Altimmune pemvidutide IMPACT MASH, Novo Nordisk ESSENCE liver safety, Madrigal Rezdiffra portal hypertension data, Eli Lilly retatrutide MASLD Phase 3 status, and Boehringer survodutide SYNCHRONIZE-1 preview at EASL plus the peptide-oncology cohort at ASCO (Bicycle, Avacta, BriaCell, BioVaxys, Crinetics, Sapience, Corbus). The Hepcludex approval Friday plus the EASL plus ASCO double-meeting structure makes this the highest-volume peptide-news week of 2026 to date.

Industry · View digest

Wegovy Pill Cumulative US Prescriptions Trajectory Going Into Memorial Day Week: 2M+ Confirmed May 18, Now Approaching 2.15M

Cumulative US Wegovy pill prescriptions, as disclosed in Novo Nordisk CEO Maziar Doustdar's May 14 commentary (>1M) and EVP Larsen's May 18 commentary on CNBC (>2M), continued to trend upward through the Memorial-Day-week lead-in. Weekly Wegovy pill volume of approximately 142,000 for the week ending May 15 — slightly above the prior week's 137,000 after the brief mid-May decline — suggests cumulative US prescriptions are now in the 2.1-2.15M range. The Wegovy pill launch (January 5, 2026) trajectory continues to outpace the comparable Wegovy injectable launch (June 2021), positioning Novo for the projected H2 2026 EU launches in UK, Germany, and Denmark. The Wegovy HD (7.2 mg injectable) CHMP positive opinion announced May 22 adds the high-dose franchise to the EU portfolio.